Vice President of Therapeutic Discovery, Amgen
The Amgen team was also the first to publish a paper on monoclonality of cell lines derived from the Opto™ CLD workflows on the Beacon system, sharing with the rest of the scientific community their strategy to validate that clones can be generated with >99% monoclonality assurance, higher overall cloning efficiency than using other well-known methods, offering what they described as a “superior clonality data package”.
As noted by Amgen’s scientists, using previous methods of hybridoma fusion for antibody discovery starts out with 0.1% of B cells surviving the fusion, not to mention the weeks it takes to grow the millions of cells for screening.
With the Beacon system you can skip the entire hybridoma model, getting to your answers faster and with more relevant data. You can directly assay the B cells and connect antibody function to gene sequence at the single-cell level.